MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
AtriCure Revenue 2011-2025 | ATRC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AtriCure
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 465 M | 399 M | 330 M | 274 M | 207 M | 231 M | 202 M | 175 M | 155 M | 130 M | 107 M | 81.9 M | 70.2 M | 64.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 465 M | 64.4 M | 207 M |
Quarterly Revenue AtriCure
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 M | 124 M | - | 116 M | 116 M | 109 M | - | 98.3 M | 101 M | 93.5 M | - | 83.2 M | 84.5 M | 74.6 M | 73.2 M | 70.5 M | 71.4 M | 59.3 M | 57.7 M | 54.8 M | 40.8 M | 53.2 M | 61.3 M | 56.6 M | 58.9 M | 54 M | 52.9 M | 49.9 M | 51.8 M | 47 M | 46.1 M | 42.2 M | 45.2 M | 41.3 M | 41.2 M | 38.3 M | 39.7 M | 35.9 M | 35.9 M | 31.4 M | 32.6 M | 29.9 M | 29.4 M | 26.7 M | 26.5 M | 24.8 M | 21.9 M | 20.1 M | 20.4 M | 19.4 M | 18.4 M | 16.1 M | 18.3 M | 17.5 M | 16.8 M | 15.2 M | 16.8 M | 15.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 136 M | 15.2 M | 51.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
2.75 B | $ 19.32 | 1.05 % | $ 9.85 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 196.18 | -0.01 % | $ 56.4 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 5.47 | -0.01 % | $ 110 M | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.71 | -1.78 % | $ 30.1 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
9.91 B | $ 80.33 | 0.26 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 6.25 | -3.55 % | $ 285 M | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 177.0 | 0.68 % | $ 5.52 B | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 148.17 | 0.81 % | $ 3.61 B | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 83.95 | -0.46 % | $ 1.88 B | USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
16 M | $ 4.93 | 1.54 % | $ 27.2 K | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 13.12 | -0.3 % | $ 536 M | USA |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 87.36 | -0.03 % | $ 5.09 B | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 82.55 | -0.03 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 116.08 | -0.56 % | $ 5.62 B | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 80.39 | 0.36 % | $ 4.05 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 8.93 | -1.71 % | $ 184 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 132.7 | -0.44 % | $ 7.07 B | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.43 | - | $ 181 M | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 578.08 | 0.16 % | $ 205 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.16 | -0.88 % | $ 22 M |  Israel |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.29 | -1.41 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
14.2 M | $ 4.98 | -4.78 % | $ 51.7 M | USA |
 |
STERIS plc
STE
|
5.46 B | $ 255.64 | 0.02 % | $ 25.2 B | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 21.99 | -0.05 % | $ 3.79 B | USA |
 |
Predictive Oncology
POAI
|
1.62 M | - | - | $ 32.4 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 39.33 | -2.65 % | $ 129 M | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 56.66 | 0.66 % | $ 206 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 14.45 | -2.76 % | $ 694 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 245.14 | 0.3 % | $ 35.8 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 11.47 | 3.66 % | $ 2.33 B | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 165.37 | -0.18 % | $ 9.21 M | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 24.95 | -1.81 % | $ 1.15 B | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.46 | 1.23 % | $ 199 M | USA |
 |
STAAR Surgical Company
STAA
|
314 M | $ 23.37 | -1.1 % | $ 1.15 B | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.82 | -0.51 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 122.75 | 0.7 % | $ 5.75 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 274.28 | -0.95 % | $ 20 B | USA |